QELBREE 200 mg/1

QELBREE 200 mg is an extended-release capsule containing viloxazine hydrochloride, used for managing certain mental health conditions. This medication is designed for oral administration and is manufactured by Supernus Pharmaceuticals, Inc.

QELBREE 200 mg is primarily used for the management of attention deficit hyperactivity disorder (ADHD) in adults. Viloxazine hydrochloride, the active ingredient, works to help improve focus and reduce impulsivity. This medication is part of a treatment plan that may include other therapies and lifestyle changes.

Common effects of QELBREE 200 mg may include changes in appetite, sleep disturbances, and mild gastrointestinal discomfort. Some users may experience dizziness or headaches. These effects vary among individuals and typically subside as the body adjusts to the medication.

QELBREE 200 mg should be stored at room temperature, away from moisture and heat. It is important to follow the prescribed dosage and administration instructions provided by a healthcare professional. Do not crush or chew the extended-release capsules.

QELBREE 200 mg may interact with certain medications, including those that affect liver enzymes. It is advisable to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol consumption should be avoided while using this medication.